EGb 761
Ginkgo biloba
NCD
mild cognitive impairment
mild neurocognitive disorder
systematic review
Journal
Neuropsychiatric disease and treatment
ISSN: 1176-6328
Titre abrégé: Neuropsychiatr Dis Treat
Pays: New Zealand
ID NLM: 101240304
Informations de publication
Date de publication:
2023
2023
Historique:
received:
07
01
2023
accepted:
04
03
2023
medline:
31
3
2023
entrez:
30
3
2023
pubmed:
31
3
2023
Statut:
epublish
Résumé
Many clinical trials testing MEDLINE, PubMed and EMBASE were searched for randomized, placebo-controlled double-blind trials of EGb 761 in mild impairment of cognitive functioning. All trials involving patients who met retrospectively applied diagnostic criteria for mild NCD were included. Trials of primary prevention of dementia and trials of combinations of medical treatments were excluded. Among 298 records found in databases and 76 further records related to EGb 761 in references of systematic reviews, 9 reports on clinical trials involving 946 patients met the pre-specified criteria for inclusion. Beneficial effects of EGb 761 were seen in neuropsychological tests (8 of 9 studies), scales for neuropsychiatric symptoms (3 of 3 studies), geriatric rating scales (1 of 2 studies) and global ratings of change (1 of 1 study). Significant effects were found in several domains of cognition (memory, speed of processing, attention and executive functioning). Among the neuropsychiatric symptoms, depression (2 of 3 studies) and anxiety (1 of 1 study) were significantly improved. No differences between EGb 761 treatment and placebo were seen with regard to the rates of adverse events. The included studies demonstrate treatment benefits of
Sections du résumé
Background
UNASSIGNED
Many clinical trials testing
Methods
UNASSIGNED
MEDLINE, PubMed and EMBASE were searched for randomized, placebo-controlled double-blind trials of EGb 761 in mild impairment of cognitive functioning. All trials involving patients who met retrospectively applied diagnostic criteria for mild NCD were included. Trials of primary prevention of dementia and trials of combinations of medical treatments were excluded.
Results
UNASSIGNED
Among 298 records found in databases and 76 further records related to EGb 761 in references of systematic reviews, 9 reports on clinical trials involving 946 patients met the pre-specified criteria for inclusion. Beneficial effects of EGb 761 were seen in neuropsychological tests (8 of 9 studies), scales for neuropsychiatric symptoms (3 of 3 studies), geriatric rating scales (1 of 2 studies) and global ratings of change (1 of 1 study). Significant effects were found in several domains of cognition (memory, speed of processing, attention and executive functioning). Among the neuropsychiatric symptoms, depression (2 of 3 studies) and anxiety (1 of 1 study) were significantly improved. No differences between EGb 761 treatment and placebo were seen with regard to the rates of adverse events.
Discussion
UNASSIGNED
The included studies demonstrate treatment benefits of
Identifiants
pubmed: 36994422
doi: 10.2147/NDT.S401231
pii: 401231
pmc: PMC10041984
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
647-660Informations de copyright
© 2023 Hort et al.
Déclaration de conflit d'intérêts
Jakub Hort received consulting fees and speaker honoraria from Dr. Willmar Schwabe GmbH & Co. KG, grants from the National Institute for Neurological Research (Programme EXCELES, ID Project No. LX22NPO5107) – Funded by the European Union – Next-Generation EU and IPE2 2. LF UK Grant No. 6980382; he also owns stock options for and is an advisory board member of Alzheon. This company is developing a treatment for Alzheimer's disease. Thomas Duning received honorariums and travel expenses from Genzyme, Shire, Bristol-Myers Squibb, Boehringer-Ingelheim Pharma, Sanofi Aventis, Eisai, Novartis, Bayer Vital, Merz Pharma, Actelion, Roche, Schwabe and Amicus to serve as a speaker and consultant. Thomas Duning received research support from Genzyme, Shire, Amicus and Actelion. To conduct studies on dementia, Thomas Duning received grants from Novartis, Merz Pharma, Roche and Biogen. Robert Hoerr is a full-time employee of Dr. Willmar Schwabe GmbH & Co. KG and receives a fixed salary. The authors report no other conflicts of interest in this work.
Références
N Engl J Med. 2005 Jun 9;352(23):2379-88
pubmed: 15829527
FASEB J. 2007 Aug;21(10):2400-8
pubmed: 17356006
Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12197-202
pubmed: 12213959
Arch Neurol. 1999 Mar;56(3):303-8
pubmed: 10190820
J Neurol Neurosurg Psychiatry. 2016 Sep;87(9):993-9
pubmed: 27010616
Int Psychogeriatr. 1992;4 Suppl 2:203-19
pubmed: 1288663
Health Psychol Res. 2022 Jan 30;10(1):31925
pubmed: 35928986
J Pharm Health Care Sci. 2015 Apr 10;1:14
pubmed: 26819725
Presse Med. 1986 Sep 25;15(31):1583-7
pubmed: 2947106
Clin Interv Aging. 2014 Nov 28;9:2065-77
pubmed: 25506211
World J Biol Psychiatry. 2019 Mar;20(3):173-189
pubmed: 28460580
J Intern Med. 2004 Sep;256(3):183-94
pubmed: 15324362
Fortschr Med. 1992 Feb 20;110(5):73-6
pubmed: 1544615
Alzheimer Dis Assoc Disord. 1997;11 Suppl 2:S13-21
pubmed: 9236948
Alzheimers Dement. 2011 May;7(3):270-9
pubmed: 21514249
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
Lancet Neurol. 2007 Aug;6(8):734-46
pubmed: 17616482
Control Clin Trials. 1996 Feb;17(1):1-12
pubmed: 8721797
Pharmacotherapy. 2011 May;31(5):490-502
pubmed: 21923430
Eur J Neurol. 2019 Sep;26(9):1161-1167
pubmed: 30927497
JAMA Neurol. 2014 Aug;71(8):961-70
pubmed: 24886908
Eur Arch Psychiatry Clin Neurosci. 2016 Apr;266(3):249-59
pubmed: 26267422
JAMA Neurol. 2018 Sep 1;75(9):1124-1131
pubmed: 29799986
Int J Geriatr Psychiatry. 2014 Oct;29(10):1087-95
pubmed: 24633934
Arzneimittelforschung. 1989 Aug;39(8):918-22
pubmed: 2684175
Neurology. 2022 May 24;98(21):e2132-e2139
pubmed: 35351783
J Prev Alzheimers Dis. 2022;9(3):507-522
pubmed: 35841252
World J Biol Psychiatry. 2020 Oct;21(8):579-594
pubmed: 32019392
Ageing Res Rev. 2021 Dec;72:101496
pubmed: 34687956
Psychopharmacol Bull. 1983;19(3):448-50
pubmed: 6635122
Lancet Neurol. 2014 Jun;13(6):614-29
pubmed: 24849862
Int Psychogeriatr. 1994 Spring;6(1):63-8
pubmed: 8054494
Arch Neurol. 1995 Jun;52(6):612-9
pubmed: 7763211
Hum Psychopharmacol. 2009 Jul;24(5):345-70
pubmed: 19551805
Alzheimers Dement (N Y). 2019 Sep 04;5:441-449
pubmed: 31517031
Int Psychogeriatr. 2018 Mar;30(3):285-293
pubmed: 28931444
World J Biol Psychiatry. 2016 Dec;17(8):622-633
pubmed: 26223956
Antioxidants (Basel). 2022 Oct 31;11(11):
pubmed: 36358538
J Prev Alzheimers Dis. 2022;9(2):197-210
pubmed: 35542991
Neurology. 1984 Jul;34(7):939-44
pubmed: 6610841
Clin Nutr. 2004 Aug;23(4):615-21
pubmed: 15297098
Int Psychogeriatr. 1997;9 Suppl 1:65-9
pubmed: 9447429
Acta Neuropathol. 2017 Aug;134(2):171-186
pubmed: 28488154
BMJ. 2021 Mar 29;372:n160
pubmed: 33781993
J Alzheimers Dis. 2019 Aug 12;71(2):513-523
pubmed: 31424411
Fortschr Med. 1988 Jun 30;106(19):408-12
pubmed: 3061905
CNS Neurosci Ther. 2021 Feb;27(2):149-162
pubmed: 33352000
J Alzheimers Dis. 2009;18(4):787-98
pubmed: 19661619
J Intern Med. 2004 Sep;256(3):240-6
pubmed: 15324367
Can Med Assoc J. 1962 Feb 10;86:257-60
pubmed: 14459267
Psychopharmacol Bull. 1988;24(4):509-14
pubmed: 3074311
J Prev Alzheimers Dis. 2020;7(3):146-151
pubmed: 32463066